ROMANO KATHRYN 4

4 · Krystal Biotech, Inc. · Filed Mar 3, 2026

Insider Transaction Report

Form 4

Period: 2026-02-27

Krystal Biotech, Inc.KRYS

ROMANO KATHRYN

Chief Accounting Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-27+7,500→ 26,068 total
Tax Payment
Common Stock
[F2][F3]
2026-02-27$275.64/sh−3,262$899,138→ 22,806 total
Exercise/Conversion
Common Stock
[F4]
2026-02-27+550→ 23,356 total
Tax Payment
Common Stock
[F5][F3]
2026-02-27$275.64/sh−240$66,154→ 23,116 total
Sale
Common Stock
[F6]
2026-03-02$267.60/sh−750$200,700→ 22,366 total
Exercise/Conversion
Performance Stock Units
[F1]
2026-02-27−7,500→ 0 total
→ Common Stock (7,500 underlying)
Exercise/Conversion
Restricted Stock Units
[F4]
2026-02-27−550→ 1,650 total
→ Common Stock (550 underlying)
Award
Stock Option (Right to Buy)
[F7]
2026-02-27+13,575→ 13,575 total
Exercise: $275.64Exp: 2036-02-26→ Common Stock (13,575 underlying)
Award
Restricted Stock Units
[F8][F9][F10]
2026-02-27+5,442→ 5,442 total
→ Common Stock (5,442 underlying)

Footnotes (10)

[F1]15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026.
[F10]The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.
[F2]Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026.
[F3]The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.
[F4]2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026.
[F5]Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026.
[F6]The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan.
[F7]The stock options vest in four equal annual installments beginning on February 27, 2027.
[F8]Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
[F9]The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.

Signature

/s/ Kathryn Romano|2026-03-03

Documents

1 file

4
wk-form4_1772580832.xmlPrimary
FORM 4